PH25908A - Novel omicron(-glucosides inhibitors - Google Patents

Novel omicron(-glucosides inhibitors

Info

Publication number
PH25908A
PH25908A PH38729A PH38729A PH25908A PH 25908 A PH25908 A PH 25908A PH 38729 A PH38729 A PH 38729A PH 38729 A PH38729 A PH 38729A PH 25908 A PH25908 A PH 25908A
Authority
PH
Philippines
Prior art keywords
omicron
glucosides
inhibitors
novel
novel omicron
Prior art date
Application number
PH38729A
Other languages
English (en)
Inventor
Jean-Bernard Ducep
Charles Danzin
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of PH25908A publication Critical patent/PH25908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/12—Acyclic radicals, not substituted by cyclic structures attached to a nitrogen atom of the saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/02—Acyclic radicals, not substituted by cyclic structures
    • C07H15/04—Acyclic radicals, not substituted by cyclic structures attached to an oxygen atom of the saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/048—Pyridine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/06—Heterocyclic radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PH38729A 1988-06-02 1989-06-01 Novel omicron(-glucosides inhibitors PH25908A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP88401340A EP0344383A1 (de) 1988-06-02 1988-06-02 Alpha-Glucosidase-Inhibitoren

Publications (1)

Publication Number Publication Date
PH25908A true PH25908A (en) 1991-12-19

Family

ID=8200392

Family Applications (1)

Application Number Title Priority Date Filing Date
PH38729A PH25908A (en) 1988-06-02 1989-06-01 Novel omicron(-glucosides inhibitors

Country Status (22)

Country Link
US (1) US5157116A (de)
EP (1) EP0344383A1 (de)
JP (1) JP2791419B2 (de)
KR (1) KR0155541B1 (de)
CN (1) CN1023803C (de)
AR (1) AR247890A1 (de)
AT (1) ATE129716T1 (de)
AU (1) AU608711B2 (de)
CA (1) CA1339740C (de)
DE (1) DE68924670T2 (de)
DK (1) DK267489A (de)
ES (1) ES2081857T3 (de)
FI (1) FI92934C (de)
GR (1) GR3018354T3 (de)
HU (1) HU203559B (de)
IE (1) IE68455B1 (de)
IL (1) IL90463A0 (de)
NO (1) NO170023C (de)
NZ (1) NZ229337A (de)
PH (1) PH25908A (de)
PT (1) PT90713B (de)
ZA (1) ZA894068B (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3936295A1 (de) * 1989-11-01 1991-05-02 Bayer Ag Verfahren zur herstellung von zwischenprodukten und zur synthese von n-(2-hydroxyethyl)-2-hydroxymethyl-3,4,5-trihydroxypiperidine
US5504078A (en) * 1990-06-08 1996-04-02 Merrell Dow Pharmaceuticals Inc. α-glucosidase inhibitors
US5844102A (en) * 1994-07-07 1998-12-01 University Of Maryland Baltimore County Glycohydrolase inhibitors, their preparation and use thereof
JP3580900B2 (ja) * 1995-04-20 2004-10-27 ホクレン農業協同組合連合会 α−グルコシダーゼ阻害剤を含む糖を主体とする組成物を有効成分とする食品及び飼料
AU4335997A (en) * 1996-09-09 1998-03-26 Wisconsin Alumni Research Foundation Human salivary proteins and fragments thereof having alpha-glucosidase inhibitory activity
GB2338235B (en) * 1997-04-15 2001-11-14 Csir Appetite suppressing plant extracts
WO1998050359A1 (en) * 1997-05-06 1998-11-12 Novo Nordisk A/S Novel heterocyclic compounds
GB2355657B (en) * 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP4486792B2 (ja) 2003-06-12 2010-06-23 学校法人近畿大学 環状オニウム化合物およびグルコシダーゼ阻害剤
US7262318B2 (en) * 2004-03-10 2007-08-28 Pfizer, Inc. Substituted heteroaryl- and phenylsulfamoyl compounds
WO2005092334A2 (en) * 2004-03-25 2005-10-06 David Priestman Use of n-substituted imino sugars for appetite suppression
US20050288340A1 (en) * 2004-06-29 2005-12-29 Pfizer Inc Substituted heteroaryl- and phenylsulfamoyl compounds
AP2007003979A0 (en) * 2004-11-23 2007-06-30 Warner Lambert Co 7-(2h-pyrazol-3-yl)-3,5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for thetreatment of lipidemia
WO2006133447A1 (en) * 2005-06-08 2006-12-14 Amicus Therapeutics, Inc. Crystalline sugar compositions and method of making
SI2027137T1 (sl) * 2005-06-08 2015-06-30 Amicus Therapeutics, Inc. Čiščenje imino in amino sladkorja
CN101228173A (zh) * 2005-06-08 2008-07-23 阿米库斯治疗学公司 三氟甲磺酸酯化的化合物的稳定化
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
GB0614947D0 (en) * 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
CN101663262B (zh) 2006-12-01 2014-03-26 百时美施贵宝公司 用于治疗动脉粥样硬化和心血管疾病的作为cetp抑制剂的n-(3-苄基)-2,2-(二苯基)-丙-1胺衍生物
US8877717B2 (en) 2007-03-12 2014-11-04 Zadec Aps Anti-diabetic extract of rooibos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
MX354786B (es) 2007-06-04 2018-03-21 Synergy Pharmaceuticals Inc Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos.
ES2522968T3 (es) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Agonistas de guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP2680874A2 (de) 2011-03-04 2014-01-08 Pfizer Inc Edn3-ähnliche peptide und ihre verwendung
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
EP2986599A1 (de) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamid-derivate zur behandlung von herz-kreislauf-erkrankungen
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
KR102431436B1 (ko) 2014-08-29 2022-08-10 테스 파마 에스.알.엘. α-아미노-β-카복시뮤콘산 세미알데히드 데카복실라제의 억제제
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
WO2018069532A1 (en) 2016-10-14 2018-04-19 Tes Pharma S.R.L. Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase
AR117122A1 (es) 2018-11-20 2021-07-14 Tes Pharma S R L INHIBIDORES DE LA ÁCIDO a-AMINO-b-CARBOXIMUCÓNICO SEMIALDEHÍDO DESCARBOXILASA
BR112021013807A2 (pt) 2019-01-18 2021-11-30 Astrazeneca Ab Inibidores de pcsk9 e seus métodos de uso

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) * 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
NO154918C (no) * 1977-08-27 1987-01-14 Bayer Ag Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
DE2830469A1 (de) * 1978-07-11 1980-01-24 Bayer Ag Herstellung von l-desoxy-nojirimycin und n-substituierten derivaten
DE2922760A1 (de) * 1979-06-05 1980-12-11 Bayer Ag Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel sowie in der tierernaehrung
GB2064527B (en) * 1979-12-08 1984-05-02 Nippon Shinyaku Co Ltd Moranoline derivatives and process for preparation thereof
DE3038901A1 (de) * 1980-10-15 1982-05-06 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von n-substituierten derivaten des 1-desoxynojirimycins
JPS61115093A (ja) * 1984-11-09 1986-06-02 Nippon Shinyaku Co Ltd モラノリン誘導体の製法
US4634765A (en) * 1984-12-18 1987-01-06 Merrell Dow Pharmaceuticals Inc. Homodisaccharide hypoglycemic agents
GB2181729B (en) * 1985-10-12 1990-04-04 Nippon Shinyaku Co Ltd Glucosylmoranoline derivatives and production thereof
DE3737523A1 (de) * 1987-11-05 1989-05-18 Bayer Ag Verwendung von substituierten hydroxypiperidinen als antivirale mittel

Also Published As

Publication number Publication date
FI892682A0 (fi) 1989-06-01
FI892682L (fi) 1989-12-03
FI92934B (fi) 1994-10-14
KR910000776A (ko) 1991-01-30
ATE129716T1 (de) 1995-11-15
IE68455B1 (en) 1996-06-26
NO892230D0 (no) 1989-06-01
CN1023803C (zh) 1994-02-16
NO892230L (no) 1989-12-04
ZA894068B (en) 1990-09-26
CA1339740C (en) 1998-03-17
GR3018354T3 (en) 1996-03-31
HUT50191A (en) 1989-12-28
JPH0225498A (ja) 1990-01-26
JP2791419B2 (ja) 1998-08-27
IL90463A0 (en) 1990-01-18
NO170023B (no) 1992-05-25
AU608711B2 (en) 1991-04-11
PT90713A (pt) 1989-12-29
US5157116A (en) 1992-10-20
AR247890A1 (es) 1995-04-28
IE891798L (en) 1989-12-02
DK267489A (da) 1989-12-03
DK267489D0 (da) 1989-06-01
NZ229337A (en) 1990-12-21
KR0155541B1 (ko) 1998-10-15
FI92934C (fi) 1995-01-25
HU203559B (en) 1991-08-28
ES2081857T3 (es) 1996-03-16
DE68924670D1 (de) 1995-12-07
PT90713B (pt) 1993-09-30
DE68924670T2 (de) 1996-05-23
NO170023C (no) 1992-09-02
CN1040032A (zh) 1990-02-28
AU3580189A (en) 1990-02-01
EP0344383A1 (de) 1989-12-06

Similar Documents

Publication Publication Date Title
PH25908A (en) Novel omicron(-glucosides inhibitors
GB2226886B (en) Electroseismic prospecting
GB8817256D0 (en) Hydrophone
IL92643A0 (en) Renin inhibitors
GB8912079D0 (en) Packaging-components
SU1592386A1 (ru) Ctaль
SU1592383A1 (ru) Ctaль
CS25787A1 (en) Inhibitor koroze
CS862387A1 (en) Smesny inhibitor koroze oceli
IE872276L (en) DOPAMINE-ß-HYDROXYLASE INHIBITORS
IE882773L (en) Suppositories
IE893832L (en) DOPAMINE-ß-HYDROXYLASE INHIBITORS
AU104083S (en) Baton
AU102774S (en) Baton
AU106611S (en) Baton
AU102239S (en) Baton
IE883340L (en) Renin inhibitors
IE883074L (en) Renin inhibitors
AU104726S (en) Plectrum
AU103025S (en) Block
GB8819319D0 (en) Block
AU101874S (en) Block
AU102719S (en) Block
GB8811857D0 (en) Hydrostatically-operating hydrophone
BG45953A1 (en) Holding section